Impact of Dermatologic Adverse Events on Quality of Life in 283 Cancer Patients: A Questionnaire Study in a Dermatology Referral Clinic
- 27 April 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in American Journal of Clinical Dermatology
- Vol. 14 (4), 327-333
- https://doi.org/10.1007/s40257-013-0021-0
Abstract
Anticancer therapies cause a wide range of dermatologic adverse events (AE). Although the frequency and severity of these events have been described, their effects on health-related quality of life (QoL) remain poorly understood, and the ones having a greater impact have not been ascertained. To assess QoL in patients on conventional versus targeted anti-cancer therapies using a dermatology-specific questionnaire. Patients (n = 283) completed the Skindex-16, a QoL questionnaire measuring the effects on three domains: symptoms, emotions, and function. Patients were grouped into two categories according to the types of oncology treatments received: (1) targeted therapies and (2) non-targeted therapies. Correlations of Skindex-16 scores with type of anti-cancer therapy, number of AEs, and specific dermatologic AEs were investigated. Significant differences between patients treated with targeted versus non-targeted therapy with regards to total Skindex-16 (p = 0.02) and emotion subdomain (p = 0.02) scores were observed. Additionally, patients on targeted therapies experienced a significantly greater number of AEs (p < 0.001) compared with patients on non-targeted therapies. Patients who exhibited epidermal growth factor receptor (EGFR) inhibitor-induced rash had higher Skindex-16 scores (p = 0.009) and higher scores in the symptom (p < 0.001), emotion (p = 0.01), and function (p = 0.001) subdomains than patients without this AE. Similar results were observed for pruritus. All p values were two sided. Dermatologic AEs are associated with a diminished QoL. Targeted therapies are associated with a significantly increased number of AEs and worse total and emotion Skindex-16 scores in comparison with non-targeted therapies. EGFR inhibitor rash and pruritus produced the greatest negative impact.Keywords
This publication has 23 references indexed in Scilit:
- The risk of nail changes with epidermal growth factor receptor inhibitors: A systematic review of the literature and meta-analysisJournal of the American Academy of Dermatology, 2012
- Dermatologic manifestations of cytotoxic therapyDermatologic Therapy, 2011
- Hand-Foot Syndrome Related to Liposomal DoxorubicinOncology Nursing Forum, 2010
- Search for Evidence-Based Approaches for the Prevention and Palliation of Hand–Foot Skin Reaction (HFSR) Caused by the Multikinase Inhibitors (MKIs)The Oncologist, 2009
- Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and SunitinibThe Oncologist, 2008
- Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of expertsEuropean Journal Of Cancer, 2008
- Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey ResultsOncology, 2007
- Mechanisms of cutaneous toxicities to EGFR inhibitorsNature Reviews Cancer, 2006
- Management of hand-foot syndrome induced by capecitabineJournal of Oncology Pharmacy Practice, 2006
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005